Henry Schein Management

Management criteria checks 2/4

Henry Schein's CEO is Stan Bergman, appointed in Jan 1989, has a tenure of 35.33 years. total yearly compensation is $10.01M, comprised of 16.2% salary and 83.8% bonuses, including company stock and options. directly owns 0.59% of the company’s shares, worth MX$904.11M. The average tenure of the management team and the board of directors is 8.3 years and 17.8 years respectively.

Key information

Stan Bergman

Chief executive officer

US$10.0m

Total compensation

CEO salary percentage	16.2%
CEO tenure	35.3yrs
CEO ownership	0.6%
Management average tenure	8.3yrs
Board average tenure	17.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Stan Bergman's remuneration changed compared to Henry Schein's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 30 2024	n/a	n/a	US$346m
Dec 30 2023	US$10m	US$2m	US$416m
Sep 30 2023	n/a	n/a	US$445m
Jul 01 2023	n/a	n/a	US$458m
Apr 01 2023	n/a	n/a	US$478m
Dec 31 2022	US$8m	US$2m	US$538m
Sep 24 2022	n/a	n/a	US$638m
Jun 25 2022	n/a	n/a	US$650m
Mar 26 2022	n/a	n/a	US$646m
Dec 25 2021	US$11m	US$2m	US$631m
Sep 25 2021	n/a	n/a	US$626m
Jun 26 2021	n/a	n/a	US$606m
Mar 27 2021	n/a	n/a	US$438m
Dec 26 2020	US$6m	US$751k	US$403m
Sep 26 2020	n/a	n/a	US$591m
Jun 27 2020	n/a	n/a	US$585m
Mar 28 2020	n/a	n/a	US$713m
Dec 28 2019	US$14m	US$1m	US$701m
Sep 28 2019	n/a	n/a	US$488m
Jun 29 2019	n/a	n/a	US$444m
Mar 30 2019	n/a	n/a	US$438m
Dec 29 2018	n/a	n/a	US$431m
Sep 29 2018	n/a	n/a	US$304m
Jun 30 2018	n/a	n/a	US$352m
Mar 31 2018	n/a	n/a	US$377m

Compensation vs Market: Stan's total compensation ($USD10.01M) is above average for companies of similar size in the MX market ($USD2.67M).

Compensation vs Earnings: Stan's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Stan Bergman (73 yo)

35.3yrs

Tenure

US$10,005,729

Compensation

Mr. Stanley M. Bergman, also known as Stan, has been the Chief Executive Officer and Executive Chairman of Henry Schein, Inc. since 1989 and has been its Executive Director since 1982. Mr. Bergman served a...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Stanley Bergman	Executive Chairman & CEO	35.3yrs	US$10.01m	0.59% MX$ 904.1m
James Breslawski	Executive Vice Chairman & President	32.3yrs	US$2.69m	0.11% MX$ 171.2m
Ronald South	Senior VP & CFO	2.1yrs	US$2.35m	0.0078% MX$ 11.9m
Michael Ettinger	Executive VP & COO	1.8yrs	US$2.97m	0.019% MX$ 28.7m
Steven Paladino	Executive Director	2.1yrs	US$265.00k	0.095% MX$ 145.8m
Mark Mlotek	Executive VP	12.3yrs	US$3.22m	0.011% MX$ 17.5m
Olga Timoshkina	VP of Corporate Finance	2.7yrs	no data	no data
Christopher Pendergast	Senior VP & CTO	6.1yrs	no data	no data
Graham Stanley	VP of Investor Relations & Strategic Finance Project Officer	no data	no data	no data
Walter Siegel	Senior VP & Chief Legal Officer	10.6yrs	no data	0.034% MX$ 52.3m
Ann Gothard	Vice President of Global Corporate Media Relations	no data	no data	no data
Lorelei McGlynn	Senior VP & Chief Human Resources Officer	11yrs	no data	0.073% MX$ 111.8m

8.3yrs

Average Tenure

63yo

Average Age

Experienced Management: HSIC *'s management team is seasoned and experienced (8.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Stanley Bergman	Executive Chairman & CEO	42.3yrs	US$10.01m	0.59% MX$ 904.1m
James Breslawski	Executive Vice Chairman & President	32.3yrs	US$2.69m	0.11% MX$ 171.2m
Steven Paladino	Executive Director	31.4yrs	US$265.00k	0.095% MX$ 145.8m
Mark Mlotek	Executive VP	28.7yrs	US$3.22m	0.011% MX$ 17.5m
Philip Laskawy	Independent Lead Director	22.3yrs	US$335.40k	0.029% MX$ 43.9m
Joseph Herring	Independent Director	8yrs	US$313.00k	0.017% MX$ 26.7m
Louis Sullivan	Chairman of Medical Advisory Board	17.8yrs	US$256.40k	no data
Norman Matthews	Member of Medical Advisory Board	no data	US$291.52k	no data
Bradley Sheares	Independent Director	14.3yrs	US$304.20k	0.0026% MX$ 4.0m
Carol Raphael	Independent Director	11.8yrs	US$282.60k	0.023% MX$ 35.1m
Kurt Kuehn	Independent Director	8yrs	US$316.40k	0.0014% MX$ 2.1m
Deborah Derby	Independent Director	3.3yrs	US$304.80k	0.00059% MX$ 904.4k

17.8yrs

Average Tenure

69yo

Average Age

Experienced Board: HSIC *'s board of directors are seasoned and experienced ( 17.8 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/05/26 14:15
End of Day Share Price	2024/02/27 00:00
Earnings	2024/03/30
Annual Earnings	2023/12/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Henry Schein, Inc. is covered by 38 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jeffrey Johnson	Baird
Ishan Majumdar	Baptista Research
Lawrence Marsh	Barclays

Henry Schein Management

Management criteria checks 2/4

Key information

Recent management updates

Henry Schein, Inc. Announces Appointment of Members to the Company’S Executive Management Committee

Henry Schein, Inc., Annual General Meeting, May 21, 2024

Independent Lead Director recently sold Mex$5.5m worth of stock

Henry Schein Appoints Carole T. Faig as New Independent Director

Recent updates

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire Acentus.

Ananym Capital Management Pushes for Changes at Henry Schein

Henry Schein, Inc. Updates Earnings Guidance for the Full Year 2024

Henry Schein, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Henry Schein, Inc.(NasdaqGS:HSIC) dropped from FTSE All-World Index (USD)

Henry Schein, Inc. Revises Earnings Guidance for the Year 2024

Henry Schein, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Henry Schein, Inc. Revises Earnings Guidance for the Year 2024

Henry Schein, Inc. to Report Q1, 2024 Results on May 07, 2024

Henry Schein, Inc. Announces Appointment of Members to the Company’S Executive Management Committee

Henry Schein, Inc. (NasdaqGS:HSIC) completed the acquisition of an unknown majority interest in TriMed, Inc.

Henry Schein, Inc., Annual General Meeting, May 21, 2024

Independent Lead Director recently sold Mex$5.5m worth of stock

Full year 2023 earnings released: EPS: US$3.19 (vs US$3.95 in FY 2022)

New minor risk - Financial position

Henry Schein, Inc. Presents Comprehensive Lineup of Solutions At the 2024 Chicago Dental Society Mid Winter Meeting

Henry Schein, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire an unknown majority interest in TriMed, Inc.

Henry Schein Appoints Carole T. Faig as New Independent Director

Henry Schein Announces Receipt of Deficiency Notice From Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

Henry Schein Announces Receipt of Deficiency Notice From Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

Henry Schein, Inc. Provides Earnings Guidance for 2023

Henry Schein, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Henry Schein, Inc. (NasdaqGS:HSIC) completed the acquisition of an unknown majority stake in Shield HealthCare, Inc.

Henry Schein, Inc. Affirms Earnings Guidance for the Full Year of 2023

Henry Schein, Inc. (NasdaqGS:HSIC) signed an agreement to acquire a majority stake in Shield HealthCare, Inc.

Henry Schein, Inc. (NasdaqGS:HSIC) acquired a majority stake in Large Practice Sales LLC.

Henry Schein, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Henry Schein, Inc. Provides Sales Guidance for the Fiscal Year 2023

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Regional Healthcare Group Pty Ltd.

Henry Schein, Inc. (NasdaqGS:HSIC) acquired Regional Healthcare Group Pty Ltd.

Henry Schein, Inc. (NasdaqGS:HSIC) agreed to acquire SIN - Sistema de Implante Nacional S.A. from Southern Cross Group.

Henry Schein, Inc. Reports Impairment Charge on Intangible Assets for the Fourth Quarter Ended December 31, 2022

Henry Schein, Inc. (NasdaqGS:HSIC) announces an Equity Buyback for $400 million worth of its shares.

Henry Schein, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Henry Schein, Inc. to Report Q3, 2022 Results on Nov 01, 2022

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources